Literature Review: Distinguishing closely-related amyloid precursors using an RNA aptamer

16 April 2019
Amyloid fibrils are misfolded proteins which have assembled to form insoluble aggregates in the form of fibers that are resistant to degradation. Amyloid formation is often associated with a disease that is specific to the proteins or localisation of the aggregate. Well known examples of amyloid diseases include Alzheimer’s disease, Diabetes type 2 […]

Literature Review: Hepatocellular Carcinoma Cell Imaging

5th March 2019
Hepatocellular carcinoma (HCC) is a common malignant cancer.  Glypican-3 (GPC3), a cellular membrane proteoglycan, is highly expressed in more than 70% of HCC patients and therefore may be an ideal biomarker for in vivo HCC diagnosis and imaging. Antibody reagents have limitations such as immunogenicity, easy degradation, and high cellular cytotoxicity effect in […]

Literature Review: Aptamers for analysis of rituximab and biosimilars

26th February 2019
Unlike chemically synthesised small molecule pharmaceuticals, biopharmaceuticals are a new generation of protein-based medicines. These biologics are usually protected by patents but as those patents expire the door is opened to biosimilar proteins which perform similarly to the original biologic. Small adjustments can affect the efficacy and stability of the biosimilar, so characterisation […]

Alternate Approach to Small Molecule Detection Verified by Multiple Assay Formats

The ELISA (enzyme-linked immunosorbent assay) is a plate-based method used to detect and quantify a variety of materials such as proteins, peptides, and small molecules. In general, the assay involves immobilization of the target (either directly or through a ‘capture reagent’), detection with a specific antibody or aptamer molecule, and quantification using a variety of […]

Literature Review: Portable Quantitative Malaria Aptasensor

30th January 2019

Malaria is a serious life-threatening disease, affecting a large section of the population mostly in tropical and subtropical low and middle income countries (Gallup and Sachs, 2001; World Malaria Report,2016). Currently, lateral flow based immuno-chromatographic tests are widely used for detection of malaria. However, these antibody based assays are usually non-quantitative in nature […]

Congratulations to Dr Mateja Vidic

1st June 2018

We are very pleased to announce that Mateja Vidic has completed and been awarded her PhD for the Development of DNA Aptamers Specific for Non-Small Cell Lung Cancer by the University of Ljubljana, Slovenija. Her experience in aptamer selection and application is a valuable asset to our lab and we are very proud […]

Appointment of Non-executive Director: Paul Armstrong

5th March, 2018

Aptamer Group Ltd is delighted to announce the appointment of Paul Armstrong to our board, effective immediately, as Non-executive Director.  Paul comes to us with a strong background in the antibody and research reagents sector, most recently with Abcam.  Paul will advise us on our strategic direction in our commercial operations and overall […]

Spotlight: Laboratory Technician, Katriona Harrison

Working at Aptamer Group:
The continued success of Aptamer Group means that the scientific team continues to grow. One member who joined us this summer is Katriona.  Now she has had the chance to establish herself, we took the opportunity to catch up with her.

Hi Katriona, please tell us a little about yourself.

I am currently a […]

Spotlight: Selection Technician, Mateja Vidic

19th September, 2017
An insight into working at Aptamer Group
Mateja joined Aptamer Group in August as a Selection Technician. Now she has had the chance to  settle in and become established in her role, we took the opportunity to catch up with her.
Can you tell us a bit about your Ph.D.?
I have just finished the research […]

  • Sales and Marketing Executive

Spotlight: Sales and Marketing Executive, Joel Sutcliffe

6th June 2017
An insight into working at Aptamer Group

Joel joined the Aptamer Group in April as Sales and Marketing Executive; now he’s established in the role we thought it would be a great time to catch up with him and see how he is getting on.

Hi Joel, firstly, what did you do before joining the company?

I […]